Loading…
Efficacy study of a new albumin-free Human Diploid Cell Rabies Vaccine (Lyssavac-HDC, Berna) in 100 severely rabies-exposed Thai patients
A newly developed human diploid cell rabies vaccine (Lyssavac-HDC), produced without added serum albumin and with an effort to remove the virus-inactivating betapropriolactone prior to addition of the gelatin, L-cysteine and potassium phosphate stabilizer, was tested for safety immunogenicity, adver...
Saved in:
| Published in: | Vaccine 1995-04, Vol.13 (6), p.593-596 |
|---|---|
| Main Authors: | , , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c417t-a9a526108dc3e22895b391e23fc4ea97af202f11e4f4f92a01b930fa5c08e0263 |
|---|---|
| cites | |
| container_end_page | 596 |
| container_issue | 6 |
| container_start_page | 593 |
| container_title | Vaccine |
| container_volume | 13 |
| creator | Wilde, Henry Glueck, Reinhard Khawplod, Pakamatz Cryz, Stanley J. Tantawichien, Terapong Thipkong, Penmas Chomchey, Pranee Prakongsri, Sompop Benjavongkulchai, Maneerat Sumboonanondha, Aree Samranwetaya, Ponsri Supakorn, Kantorn Sitprija, Visith |
| description | A newly developed human diploid cell rabies vaccine (Lyssavac-HDC), produced without added serum albumin and with an effort to remove the virus-inactivating betapropriolactone prior to addition of the gelatin, L-cysteine and potassium phosphate stabilizer, was tested for safety immunogenicity, adverse reactions and efficacy in 100 severely rabies-exposed Thais. All patients also received human rabies immune globulin and vaccine was administered using the conventional 5-dose intramuscular schedule of one dose on days 0, 3, 7, 14 and 28. One hundred percent of a subgroup of 40 subjects, where blood had been collected, had neutralizing antibodies greater than 0.5 IU ml
−1 on days 28 and 90 and all had detectable titers on days 7, 14, 28, 90, 180 and 360. All patients could be followed for at least 1 year and remained well. No significant side-effects from this vaccine were noted. |
| doi_str_mv | 10.1016/0264-410X(94)00049-S |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_16837906</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>0264410X9400049S</els_id><sourcerecordid>16837906</sourcerecordid><originalsourceid>FETCH-LOGICAL-c417t-a9a526108dc3e22895b391e23fc4ea97af202f11e4f4f92a01b930fa5c08e0263</originalsourceid><addsrcrecordid>eNp9kc9u1DAQhy0EKtvCG4DkA0KthMF2nE18QYJtYZFWQqIFcbMmzlgYJU5qJ1vyCLw12T_aI6c5zPcbzXxDyAvB3woulu-4XCqmBP95qdUV51xpdvuILERZZEzmonxMFifkKTlP6fcM5ZnQZ-SsUGVWlHxB_t445y3YiaZhrCfaOQo04AOFphpbH5iLiHQ9thDote-bztd0hU1Dv0HlMdEfYK0PSC83U0qwBcvW16s39CPGAFfUByo4pwm3GLGZaNyHGP7pu4Q1vfsFnvYweAxDekaeOGgSPj_WC_L9083das02Xz9_WX3YMKtEMTDQkMul4GVtM5Sy1HmVaYEyc1Yh6AKc5NIJgcoppyVwUemMO8gtL3H2kV2Q14e5fezuR0yDaX2y80kQsBuTEctZjeY7UB1AG7uUIjrTR99CnIzgZvcBs9NrdnqNVmb_AXM7x14e549Vi_UpdFQ-918d-5AsNC5CsD6dsIwLpffY-wOGs4utx2iSnT1ZrH1EO5i68__f4x8rb6F1</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>16837906</pqid></control><display><type>article</type><title>Efficacy study of a new albumin-free Human Diploid Cell Rabies Vaccine (Lyssavac-HDC, Berna) in 100 severely rabies-exposed Thai patients</title><source>ScienceDirect Freedom Collection 2022-2024</source><creator>Wilde, Henry ; Glueck, Reinhard ; Khawplod, Pakamatz ; Cryz, Stanley J. ; Tantawichien, Terapong ; Thipkong, Penmas ; Chomchey, Pranee ; Prakongsri, Sompop ; Benjavongkulchai, Maneerat ; Sumboonanondha, Aree ; Samranwetaya, Ponsri ; Supakorn, Kantorn ; Sitprija, Visith</creator><creatorcontrib>Wilde, Henry ; Glueck, Reinhard ; Khawplod, Pakamatz ; Cryz, Stanley J. ; Tantawichien, Terapong ; Thipkong, Penmas ; Chomchey, Pranee ; Prakongsri, Sompop ; Benjavongkulchai, Maneerat ; Sumboonanondha, Aree ; Samranwetaya, Ponsri ; Supakorn, Kantorn ; Sitprija, Visith</creatorcontrib><description>A newly developed human diploid cell rabies vaccine (Lyssavac-HDC), produced without added serum albumin and with an effort to remove the virus-inactivating betapropriolactone prior to addition of the gelatin, L-cysteine and potassium phosphate stabilizer, was tested for safety immunogenicity, adverse reactions and efficacy in 100 severely rabies-exposed Thais. All patients also received human rabies immune globulin and vaccine was administered using the conventional 5-dose intramuscular schedule of one dose on days 0, 3, 7, 14 and 28. One hundred percent of a subgroup of 40 subjects, where blood had been collected, had neutralizing antibodies greater than 0.5 IU ml
−1 on days 28 and 90 and all had detectable titers on days 7, 14, 28, 90, 180 and 360. All patients could be followed for at least 1 year and remained well. No significant side-effects from this vaccine were noted.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/0264-410X(94)00049-S</identifier><identifier>PMID: 7483780</identifier><identifier>CODEN: VACCDE</identifier><language>eng</language><publisher>Oxford: Elsevier Ltd</publisher><subject>Adolescent ; Adult ; Antibodies, Viral - blood ; Biological and medical sciences ; Bites and Stings ; Child ; Child, Preschool ; Diploidy ; Female ; Follow-Up Studies ; Fundamental and applied biological sciences. Psychology ; Human Diploid Cell Rabies Vaccine ; Humans ; Male ; Microbiology ; Middle Aged ; Prospective Studies ; Rabies - epidemiology ; Rabies - prevention & control ; rabies vaccine ; rabies vaccine efficacy ; rabies vaccine reactions ; Rabies Vaccines - therapeutic use ; serum sickness ; Thailand ; Thailand - epidemiology ; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies ; Virology</subject><ispartof>Vaccine, 1995-04, Vol.13 (6), p.593-596</ispartof><rights>1995</rights><rights>1996 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c417t-a9a526108dc3e22895b391e23fc4ea97af202f11e4f4f92a01b930fa5c08e0263</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=3014980$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/7483780$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wilde, Henry</creatorcontrib><creatorcontrib>Glueck, Reinhard</creatorcontrib><creatorcontrib>Khawplod, Pakamatz</creatorcontrib><creatorcontrib>Cryz, Stanley J.</creatorcontrib><creatorcontrib>Tantawichien, Terapong</creatorcontrib><creatorcontrib>Thipkong, Penmas</creatorcontrib><creatorcontrib>Chomchey, Pranee</creatorcontrib><creatorcontrib>Prakongsri, Sompop</creatorcontrib><creatorcontrib>Benjavongkulchai, Maneerat</creatorcontrib><creatorcontrib>Sumboonanondha, Aree</creatorcontrib><creatorcontrib>Samranwetaya, Ponsri</creatorcontrib><creatorcontrib>Supakorn, Kantorn</creatorcontrib><creatorcontrib>Sitprija, Visith</creatorcontrib><title>Efficacy study of a new albumin-free Human Diploid Cell Rabies Vaccine (Lyssavac-HDC, Berna) in 100 severely rabies-exposed Thai patients</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>A newly developed human diploid cell rabies vaccine (Lyssavac-HDC), produced without added serum albumin and with an effort to remove the virus-inactivating betapropriolactone prior to addition of the gelatin, L-cysteine and potassium phosphate stabilizer, was tested for safety immunogenicity, adverse reactions and efficacy in 100 severely rabies-exposed Thais. All patients also received human rabies immune globulin and vaccine was administered using the conventional 5-dose intramuscular schedule of one dose on days 0, 3, 7, 14 and 28. One hundred percent of a subgroup of 40 subjects, where blood had been collected, had neutralizing antibodies greater than 0.5 IU ml
−1 on days 28 and 90 and all had detectable titers on days 7, 14, 28, 90, 180 and 360. All patients could be followed for at least 1 year and remained well. No significant side-effects from this vaccine were noted.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Antibodies, Viral - blood</subject><subject>Biological and medical sciences</subject><subject>Bites and Stings</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Diploidy</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Human Diploid Cell Rabies Vaccine</subject><subject>Humans</subject><subject>Male</subject><subject>Microbiology</subject><subject>Middle Aged</subject><subject>Prospective Studies</subject><subject>Rabies - epidemiology</subject><subject>Rabies - prevention & control</subject><subject>rabies vaccine</subject><subject>rabies vaccine efficacy</subject><subject>rabies vaccine reactions</subject><subject>Rabies Vaccines - therapeutic use</subject><subject>serum sickness</subject><subject>Thailand</subject><subject>Thailand - epidemiology</subject><subject>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies</subject><subject>Virology</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1995</creationdate><recordtype>article</recordtype><recordid>eNp9kc9u1DAQhy0EKtvCG4DkA0KthMF2nE18QYJtYZFWQqIFcbMmzlgYJU5qJ1vyCLw12T_aI6c5zPcbzXxDyAvB3woulu-4XCqmBP95qdUV51xpdvuILERZZEzmonxMFifkKTlP6fcM5ZnQZ-SsUGVWlHxB_t445y3YiaZhrCfaOQo04AOFphpbH5iLiHQ9thDote-bztd0hU1Dv0HlMdEfYK0PSC83U0qwBcvW16s39CPGAFfUByo4pwm3GLGZaNyHGP7pu4Q1vfsFnvYweAxDekaeOGgSPj_WC_L9083das02Xz9_WX3YMKtEMTDQkMul4GVtM5Sy1HmVaYEyc1Yh6AKc5NIJgcoppyVwUemMO8gtL3H2kV2Q14e5fezuR0yDaX2y80kQsBuTEctZjeY7UB1AG7uUIjrTR99CnIzgZvcBs9NrdnqNVmb_AXM7x14e549Vi_UpdFQ-918d-5AsNC5CsD6dsIwLpffY-wOGs4utx2iSnT1ZrH1EO5i68__f4x8rb6F1</recordid><startdate>19950401</startdate><enddate>19950401</enddate><creator>Wilde, Henry</creator><creator>Glueck, Reinhard</creator><creator>Khawplod, Pakamatz</creator><creator>Cryz, Stanley J.</creator><creator>Tantawichien, Terapong</creator><creator>Thipkong, Penmas</creator><creator>Chomchey, Pranee</creator><creator>Prakongsri, Sompop</creator><creator>Benjavongkulchai, Maneerat</creator><creator>Sumboonanondha, Aree</creator><creator>Samranwetaya, Ponsri</creator><creator>Supakorn, Kantorn</creator><creator>Sitprija, Visith</creator><general>Elsevier Ltd</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7T5</scope><scope>7U9</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope></search><sort><creationdate>19950401</creationdate><title>Efficacy study of a new albumin-free Human Diploid Cell Rabies Vaccine (Lyssavac-HDC, Berna) in 100 severely rabies-exposed Thai patients</title><author>Wilde, Henry ; Glueck, Reinhard ; Khawplod, Pakamatz ; Cryz, Stanley J. ; Tantawichien, Terapong ; Thipkong, Penmas ; Chomchey, Pranee ; Prakongsri, Sompop ; Benjavongkulchai, Maneerat ; Sumboonanondha, Aree ; Samranwetaya, Ponsri ; Supakorn, Kantorn ; Sitprija, Visith</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c417t-a9a526108dc3e22895b391e23fc4ea97af202f11e4f4f92a01b930fa5c08e0263</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1995</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Antibodies, Viral - blood</topic><topic>Biological and medical sciences</topic><topic>Bites and Stings</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Diploidy</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Human Diploid Cell Rabies Vaccine</topic><topic>Humans</topic><topic>Male</topic><topic>Microbiology</topic><topic>Middle Aged</topic><topic>Prospective Studies</topic><topic>Rabies - epidemiology</topic><topic>Rabies - prevention & control</topic><topic>rabies vaccine</topic><topic>rabies vaccine efficacy</topic><topic>rabies vaccine reactions</topic><topic>Rabies Vaccines - therapeutic use</topic><topic>serum sickness</topic><topic>Thailand</topic><topic>Thailand - epidemiology</topic><topic>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies</topic><topic>Virology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wilde, Henry</creatorcontrib><creatorcontrib>Glueck, Reinhard</creatorcontrib><creatorcontrib>Khawplod, Pakamatz</creatorcontrib><creatorcontrib>Cryz, Stanley J.</creatorcontrib><creatorcontrib>Tantawichien, Terapong</creatorcontrib><creatorcontrib>Thipkong, Penmas</creatorcontrib><creatorcontrib>Chomchey, Pranee</creatorcontrib><creatorcontrib>Prakongsri, Sompop</creatorcontrib><creatorcontrib>Benjavongkulchai, Maneerat</creatorcontrib><creatorcontrib>Sumboonanondha, Aree</creatorcontrib><creatorcontrib>Samranwetaya, Ponsri</creatorcontrib><creatorcontrib>Supakorn, Kantorn</creatorcontrib><creatorcontrib>Sitprija, Visith</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wilde, Henry</au><au>Glueck, Reinhard</au><au>Khawplod, Pakamatz</au><au>Cryz, Stanley J.</au><au>Tantawichien, Terapong</au><au>Thipkong, Penmas</au><au>Chomchey, Pranee</au><au>Prakongsri, Sompop</au><au>Benjavongkulchai, Maneerat</au><au>Sumboonanondha, Aree</au><au>Samranwetaya, Ponsri</au><au>Supakorn, Kantorn</au><au>Sitprija, Visith</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy study of a new albumin-free Human Diploid Cell Rabies Vaccine (Lyssavac-HDC, Berna) in 100 severely rabies-exposed Thai patients</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>1995-04-01</date><risdate>1995</risdate><volume>13</volume><issue>6</issue><spage>593</spage><epage>596</epage><pages>593-596</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><coden>VACCDE</coden><abstract>A newly developed human diploid cell rabies vaccine (Lyssavac-HDC), produced without added serum albumin and with an effort to remove the virus-inactivating betapropriolactone prior to addition of the gelatin, L-cysteine and potassium phosphate stabilizer, was tested for safety immunogenicity, adverse reactions and efficacy in 100 severely rabies-exposed Thais. All patients also received human rabies immune globulin and vaccine was administered using the conventional 5-dose intramuscular schedule of one dose on days 0, 3, 7, 14 and 28. One hundred percent of a subgroup of 40 subjects, where blood had been collected, had neutralizing antibodies greater than 0.5 IU ml
−1 on days 28 and 90 and all had detectable titers on days 7, 14, 28, 90, 180 and 360. All patients could be followed for at least 1 year and remained well. No significant side-effects from this vaccine were noted.</abstract><cop>Oxford</cop><pub>Elsevier Ltd</pub><pmid>7483780</pmid><doi>10.1016/0264-410X(94)00049-S</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0264-410X |
| ispartof | Vaccine, 1995-04, Vol.13 (6), p.593-596 |
| issn | 0264-410X 1873-2518 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_16837906 |
| source | ScienceDirect Freedom Collection 2022-2024 |
| subjects | Adolescent Adult Antibodies, Viral - blood Biological and medical sciences Bites and Stings Child Child, Preschool Diploidy Female Follow-Up Studies Fundamental and applied biological sciences. Psychology Human Diploid Cell Rabies Vaccine Humans Male Microbiology Middle Aged Prospective Studies Rabies - epidemiology Rabies - prevention & control rabies vaccine rabies vaccine efficacy rabies vaccine reactions Rabies Vaccines - therapeutic use serum sickness Thailand Thailand - epidemiology Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies Virology |
| title | Efficacy study of a new albumin-free Human Diploid Cell Rabies Vaccine (Lyssavac-HDC, Berna) in 100 severely rabies-exposed Thai patients |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T07%3A20%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20study%20of%20a%20new%20albumin-free%20Human%20Diploid%20Cell%20Rabies%20Vaccine%20(Lyssavac-HDC,%20Berna)%20in%20100%20severely%20rabies-exposed%20Thai%20patients&rft.jtitle=Vaccine&rft.au=Wilde,%20Henry&rft.date=1995-04-01&rft.volume=13&rft.issue=6&rft.spage=593&rft.epage=596&rft.pages=593-596&rft.issn=0264-410X&rft.eissn=1873-2518&rft.coden=VACCDE&rft_id=info:doi/10.1016/0264-410X(94)00049-S&rft_dat=%3Cproquest_cross%3E16837906%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c417t-a9a526108dc3e22895b391e23fc4ea97af202f11e4f4f92a01b930fa5c08e0263%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=16837906&rft_id=info:pmid/7483780&rfr_iscdi=true |